The ROCA^® Test
for Ovarian Cancer

Determines a woman’s risk
of having ovarian cancer.

To be connected to a UK private
clinician offering the ROCA Test

The Importance of Early Detection

21

women in the UK are diagnosed with ovarian cancer every day.¹

6^th

most common cause of cancer-related deaths in women in the UK.²

93^%

of women survive for at least 5 years if cancer is caught in the earliest stage.³

13^%

of women survive 5 years if cancer caught in the latest stage.³

Eligibility

The ROCA Test is intended for women who are between 35 and 85 years old who have tested positive for BRCA1 or BRCA2 gene mutation and who wish to delay risk reducing surgery.

The ROCA Test is available through a number of private clinicians across the UK. Any woman interested in having survellance using the ROCA Test must have a consultation with a clinician, so that she can understand the latest clinical evidence, and gain an informed view on the benefits and risks of using the ROCA Test. During the consultation, the clinician will assess your risk of ovarian cancer and your suitability for the test. Anyone interested should please get in touch with us at rocatest@genincode.com and we can find a clinician near you.

Learn more about the ROCA Test

News

An increase in early-stage ovarian cancer detected in women using the ROCA test.

In November 2022, the Journal of Medical Genetics published a paper that presented the results of a pilot national ovarian cancer surveillance programme using the ROCA Test, for women with alterations in the BRCA1 and BRCA2 genes.

Ovarian Cancer Surveillance using the ROCA Test: The Evidence Explained

In November 2022, the Journal of Medical Genetics published a paper that presents the results of a pilot national surveillance programme using the ROCA Test, for women with alterations in the BRCA1 and BRCA2 genes. The study was called ALDO, meaning ‘Avoiding Late Diagnosis of Ovarian cancer’.

Cookie Policy

The ROCA® Test for Ovarian Cancer